Juhász Emese, Krizsán Gergely, Lengyel György, Grósz Gábor, Pongrácz Júlia, Kristóf Katalin
Diagnostic Laboratory of Clinical Microbiology, Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary.
Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary.
Ann Clin Microbiol Antimicrob. 2014 Dec 31;13:333. doi: 10.1186/s12941-014-0058-9.
Stenotrophomonas maltophilia is an important opportunistic, mainly nosocomial pathogen that emerged in the last decades worldwide. Due to its inherent extended antibiotic resistance, therapeutic options are strongly limited. New resistance mechanisms in S. maltophilia make antibiotic therapy even more difficult. The aim of our study was to investigate the antimicrobial resistance of S. maltophilia isolates collected in our laboratory and to reveal related clinical background.
Consecutive non-duplicate S. maltophilia isolates (n = 160) were collected in a three-year period. Conventional methods, automated identification system and MALDI-TOF MS was used for identification, ERIC-PCR for genetic relationship analysis and broth microdilution method to determine the susceptibility for trimethoprim/sulfamethoxazole (SXT), ciprofloxacin, levofloxacin, moxifloxacin, colistin, doxycycline and tigecycline. Clinical final reports were used retrospectively to collect clinical information.
ERIC-PCR revealed large heterogeneity. Trimethoprim/sulfamethoxazole, moxifloxacin and levofloxacin were found to be the most effective agents with MIC50/MIC90 0.5/1, 0.25/1, 1/2 mg/l, respectively. Seventy percent of patients with S. maltophilia infection were treated in intensive care units. All-cause mortality rate was 45%. Nearly 70% of the isolates were collected from polymicrobial infections/colonizations.
Trimethoprim/sulfamethoxazole is the most potent antibiotic agent against S. maltophilia. In case of SXT hypersensitivity, intolerance or resistance, fluoroquinolones are alternative therapeutic options. Missing clinical breakpoints, consensus antibiotic susceptibility testing guidelines and clinical trials make the interpretation of antibiotic susceptibility testing results difficult. The indirect pathogenicity of S. maltophilia in polymicrobial infections or colonizations has to be taken into consideration.
嗜麦芽窄食单胞菌是一种重要的机会致病菌,主要为医院内病原菌,在过去几十年中在全球范围内出现。由于其固有的广泛抗生素耐药性,治疗选择受到极大限制。嗜麦芽窄食单胞菌新的耐药机制使抗生素治疗更加困难。我们研究的目的是调查在我们实验室收集的嗜麦芽窄食单胞菌分离株的抗菌耐药性,并揭示相关的临床背景。
在三年期间收集连续的非重复嗜麦芽窄食单胞菌分离株(n = 160)。使用传统方法、自动化鉴定系统和基质辅助激光解吸电离飞行时间质谱进行鉴定,采用ERIC-PCR进行遗传关系分析,并使用肉汤微量稀释法测定对甲氧苄啶/磺胺甲恶唑(SXT)、环丙沙星、左氧氟沙星、莫西沙星、黏菌素、多西环素和替加环素的敏感性。回顾性使用临床最终报告收集临床信息。
ERIC-PCR显示出很大的异质性。发现甲氧苄啶/磺胺甲恶唑、莫西沙星和左氧氟沙星是最有效的药物,MIC50/MIC90分别为0.5/1、0.25/1、1/2 mg/l。70%的嗜麦芽窄食单胞菌感染患者在重症监护病房接受治疗。全因死亡率为45%。近70%的分离株来自多微生物感染/定植。
甲氧苄啶/磺胺甲恶唑是针对嗜麦芽窄食单胞菌最有效的抗生素。如果对SXT过敏、不耐受或耐药,氟喹诺酮类是替代治疗选择。缺乏临床断点、共识性抗生素敏感性试验指南和临床试验使得抗生素敏感性试验结果难以解释。必须考虑嗜麦芽窄食单胞菌在多微生物感染或定植中的间接致病性。